Drug Profile
Research programme: neuraminidase inhibitors - Gilead Sciences
Alternative Names: GS 4071 analogues research programme - Gilead Sciences; Neuraminidase inhibitors research programme - Gilead SciencesLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Gilead Sciences
- Class
- Mechanism of Action Neuraminidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Influenza virus infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Influenza-virus-infections in USA
- 02 Apr 2009 Preclinical trials in Influenza virus infections in USA underway(unspecified route)
- 26 Apr 2001 New profile